65,437 trials
Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
Primary: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4) — -4.63; 0.37 Percent Change
Myopia · Astigmatism · Presbyopia
Primary: Overall Comfort — 8.6 Units on a scale
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks) — -16.8; -10.6 mm Hg
Hyperphosphatemia · Chronic Kidney Disease
Primary: Change in Serum Inorganic Phosphorus at the End of Treatment From Baseline — -0.26; -0.20 mg/dL
Fibromyalgia
Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline — -1.03; -1.48 Scores on a…
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Asthma
Primary: Change From Baseline in Prebronchodilator Clinic-Measured, Percent-Predicted Forced Expiratory Volume in 1 Second — 2.44; 0.48; 3.22; 2.59 Percent predicted — p=0.802
Myocardial Ischemia · Coronary Artery Stenosis · Coronary Disease
Primary: Target Lesion Failure (TLF) — 4.5; 7.7 percentage of participants
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Fibromyalgia
Primary: Cumulative Number of Medications Taken for Fibromyalgia (FM) Over 12 Months — 5.2 medications
Asthma
Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up
Rheumatoid Arthritis
Primary: Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period — 70; 44; 42 Participants — p=<0.001
Depression
Primary: 20-Item Symptom Checklist Depression Scale — 0.95; 1.17 units on a scale
Breast Cancer
Primary: Pathologic Assessment After Study Treatment — 18; 16; 30 participants